BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tavalisse (fostamatinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tavalisse (fostamatinib)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05904093-5985@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270514
DTEND;VALUE=DATE:20270515
SUMMARY:Tavalisse (fostamatinib): Phase 1 readout est. (NCT05904093)
DESCRIPTION:Tavalisse (fostamatinib)\, phase 1.\nStudy: Study to Evaluate t
 he Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects
  With Stable Sickle Cell Disease\nEstimated primary completion: 14 May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/fostamatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05904093
URL:https://assetmemo.bio/drug/fostamatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564207-5985@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tavalisse (fostamatinib): Phase 2 readout est. (NCT06564207)
DESCRIPTION:Tavalisse (fostamatinib)\, phase 2.\nStudy: Fostamatinib for Tr
 eating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults\n
 Estimated primary completion: 31 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/fostamatinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06564207
URL:https://assetmemo.bio/drug/fostamatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06639724-5985@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tavalisse (fostamatinib): Phase 1 readout est. (NCT06639724)
DESCRIPTION:Tavalisse (fostamatinib)\, phase 1.\nStudy: Perioperative Fosta
 matinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cance
 r\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/fostamatinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06639724
URL:https://assetmemo.bio/drug/fostamatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948097-5985@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Tavalisse (fostamatinib): Phase 1 readout est. (NCT06948097)
DESCRIPTION:Tavalisse (fostamatinib)\, phase 1.\nStudy: Syk Inhibition in M
 Itigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safe
 ty and Tolerability of Fostamatinib in Lung Transplant Patients With Donor
 -Specific Antibodies\nEstimated primary completion: 14 July 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/fostamatinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06948097
URL:https://assetmemo.bio/drug/fostamatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06233110-5985@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Tavalisse (fostamatinib): Phase 1 readout est. (NCT06233110)
DESCRIPTION:Tavalisse (fostamatinib)\, phase 1.\nStudy: Ruxolitinib Plus Fo
 stamatinib for Steroid Refractory cGvHD\nEstimated primary completion: 1 J
 anuary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fostamat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06233110
URL:https://assetmemo.bio/drug/fostamatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
